Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes
- DOI
- 10.1038/s41698-021-00237-5
- Published
- 2021-11-29
- Container
- npj Precision Oncology
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1038/s41698-021-00237-5,
title = {Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes},
author = {Gabriela Palma and Faisal Khurshid and Kevin Lu and Brian Woodward and Hatim Husain},
year = {2021},
journal = {npj Precision Oncology},
doi = {10.1038/s41698-021-00237-5},
url = {https://doi.org/10.1038/s41698-021-00237-5}
}RIS
TY - JOUR TI - Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes AU - Gabriela Palma AU - Faisal Khurshid AU - Kevin Lu AU - Brian Woodward AU - Hatim Husain PY - 2021 JO - npj Precision Oncology DO - 10.1038/s41698-021-00237-5 UR - https://doi.org/10.1038/s41698-021-00237-5 ER -
APA
Palma, G., Khurshid, F., Lu, K., Woodward, B., & Husain, H. (2021). Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes. npj Precision Oncology. https://doi.org/10.1038/s41698-021-00237-5
Source records
- crossref · retrieved 2026-09-25T19:35:59.042Z